Diagnostic pathways to Alzheimer disease costs incurred in a medicare population

Alzheimer Disease and Associated Disorders

Volumn 29, Issue 4, 2015, Pages 330-337

  Gilden, Daniel M ^a   Kubisiak, Joanna M ^a   Sarsour, Khaled ^b   Hunter, Craig A ^c  

^a JEN Assoct   (United States)

^b GENENTECH INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer disease; Dementia; Disease progression; Econometrics; Health service utilization

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; COHORT ANALYSIS; ECONOMICS; TIME FACTOR; TRENDS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; TIME FACTORS; UNITED STATES;

EID: 84948082588     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000070     Document Type: Article

References (27)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
2. Luengo-Fernandez R, Leal J, Gray A. Dementia 2010: The Economic Burden of Dementia and Associated Research Funding in the United Kingdom. Cambridge, UK: Alzheimer's Research Trust; 2010.
3. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012;8:131-168.
4. Oremus M, Aguilar SC. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics. 2011;29:141-156.
5. Bentkover J, Cai S, Makineni R, et al. Road to the nursing home: costs and disease progression among Medicare beneficiaries with ADRD. Am J Alzheimers Dis Other Demen. 2012;27:90-99.
6. Lin PJ, Neumann PJ. The economics of mild cognitive impairment. Alzheimers Dement. 2013;9:58-62.
7. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-292.
8. Albert SM, Glied S, Andrews H, et al. Primary care expenditures before the onset of Alzheimer's disease. Neurology. 2002;59:573-578.
9. van Vliet D, de Vugt ME, Bakker C, et al. Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychol Med. 2013;43:423-432.
10. Ganguli M, Snitz BE, Saxton JA, et al. Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol. 2011;68:761-767.
11. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125-132.
12. Gold M, Jacobson G, Damico A, et al. Medicare advantage enrollment market update. 2011; 8228. Available at: http://www.kff.org/medicare/upload/8228.pdf. Accessed May 14, 2012.
13. Sands LP, Xu H, Weiner M, et al. Comparison of resource utilization for Medicaid dementia patients using nursing homes versus home and community based waivers for long-term care. Med Care. 2008;46:449-453.
14. Schwarzkopf L, Menn P, Leidl R, et al. Are community-living and institutionalized dementia patients cared for differently? Evidence on service utilization and costs of care from German insurance claims data. BMC Health Serv Res. 2013;13:2.
15. Gilden DM, Kubisiak J, Zbrozek AS. The economic burden of Medicare-eligible patients by multiple sclerosis type. Value Health. 2011;14:61-69.
16. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25-32.
17. Johnson DK, Storandt M, Morris JC, et al. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol. 2009;66:1254-1259.
18. Galvin JE, Powlishta KK, Wilkins K, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005;62:758-765.
19. Malone DC, McLaughlin TP, Wahl PM, et al. Burden of Alzheimer's disease and association with negative health outcomes. Am J Manag Care. 2009;15:481-488.
20. Lin PJ, Fillit HM, Cohen JT, et al. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. Alzheimers Dement. 2013;9:30-38.
21. Phelan EA, Borson S, Grothaus L, et al. Association of incident dementia with hospitalizations. JAMA. 2012;307:165-172.
22. Weimer DL, Sager MA. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes. Alzheimers Dement. 2009;5:215-226.
23. Fillit H, Geldmacher DS, Welter RT, et al. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J Am Geriatr Soc. 2002;50:1871-1878.
24. Bradford A, Kunik ME, Schulz P, et al. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23:306-314.
25. Lin PJ, Kaufer DI, Maciejewski ML, et al. An examination of Alzheimer's disease case definitions using Medicare claims and survey data. Alzheimers Dement. 2010;6:334-341.
26. Taylor DH Jr, Østbye T, Langa KM, et al. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009;17:807-815.
27. Rosenberg PB, Mielke MM, Appleby BS, et al. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21: 1116-1124.